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Reverse transcriptase (RT) is a key enzyme in viral replication and susceptibility to ART and a crucial target of immunotherapy
against drug-resistant HIV-1. RT induces oxidative stress which undermines the attempts to make it immunogenic. We
hypothesized that artiﬁcial secretion may reduce the stress and make RT more immunogenic. Inactivated multidrug-resistant
RT (RT1.14opt-in) was N-terminally fused to the signal providing secretion of NS1 protein of TBEV (Ld) generating optimized
inactivated Ld-carrying enzyme RT1.14oil. Promotion of secretion prohibited proteasomal degradation increasing the half-life
and content of RT1.14oil in cells and cell culture medium, drastically reduced the residual polymerase activity, and
downmodulated oxidative stress. BALB/c mice were DNA-immunized with RT1.14opt-in or parental RT1.14oil by intradermal
injections with electroporation. Fluorospot and ELISA tests revealed that RT1.14opt-in and RT1.14oil induced IFN-γ/IL-2,
RT1.14opt-in induced granzyme B, and RT1.14oil induced perforin production. Perforin secretion correlated with coproduction
of IFN-γ and IL-2 (R = 0 97). Both DNA immunogens induced strong anti-RT antibody response. Ld peptide was not
immunogenic. Thus, Ld-driven secretion inferred little change to RT performance in DNA immunization. Positive outcome was
the abrogation of polymerase activity increasing safety of RT-based DNA vaccines. Identiﬁcation of the molecular determinants
of low cellular immunogenicity of RT requires further studies.
1. Introduction
Starting from the ﬁrst DNA immunization in 1991, multiple
gene-based HIV vaccines have undergone preclinical and
clinical trials [1–3]. Several of them that initially aimed to
induce strong T cell responses failed to do so indicating a
necessity to optimize both genes and their combinations.
Several preclinical and clinical studies employed HIV pol
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gene, full-length or in fragments [4–6]. Plasmids encoding
some of the pol gene products, as protease and integrase, were
shown to be immunogenic in both preclinical and clinical tri-
als [7–10]. At the same time, numerous trials showed an
impaired immunogenicity of HIV-1 reverse transcriptase
(RT) [11–13]. A recent study by Garrod et al. compared the
performance in C57BL/6 mice of DNA vaccines encoding
single HIV antigens in combination with HIV gag- and
pol-based DNA immunogens. The eﬃcacy of vaccination
was tested by challenge with a chimeric EcoHIV virus that
can infect mice [14]. At 60 days, there was signiﬁcantly lower
frequency of induced antigen-speciﬁc CD8(+) T cells in the
spleens of pCMVgag-pol-vaccinated mice compared with
mice immunized with single pCMVgag. Furthermore, while
short-term viral control of EcoHIV was similar for gag- and
gag-pol DNA-vaccinated mice, only gag DNA-vaccinated
ones were able to control EcoHIV two months postvaccina-
tion, indicating that inclusion of the HIV pol gene may
reduce the durable control over viral replication [14].
HIV enzymes encoded by pol gene, including RT, are cru-
cial if aiming at immunotherapeutic vaccination which
would prevent drug resistance in HIV infection [15]. Potent
immunogenic performance of all three HIV enzymes is a pre-
requisite of the eﬃcacy of such immunotherapy. We and
others performed series of studies aimed to improve the
immunogenicity of RT, a key enzyme determining HIV-1
resistance to antiretroviral therapy, but with a limited success
[12, 13, 16–18]. Lately, we found that cells expressing HIV-1
RT produce reactive oxygen species (ROS) and express high
levels of phase II detoxifying enzymes that interfere with the
immune response against this enzyme [19, 20]. Oxidative
stress is induced by awide panel of RTvariants, drug-resistant,
expressed from viral and expression-optimized genes, enzy-
matically active and inactive [19] indicating that the ability to
induce oxidative stress and oxidative stress response is a prop-
erty of a domain (domains) within the protein rather than the
consequence of its enzymatic activity. We hypothesized that
cellular immunogenicity of HIV RT in DNA immunization
may be increased by decreasing the levels of this stress-
inducing protein in the expressing cells.
We tested if this is the case by artiﬁcially promoting RT
export. For this, we provided a multidrug-resistant variant
of HIV-1 RT (RT1.14) [16], complemented for safety sake,
with mutations inhibiting polymerase and RNase H activity,
with a leader signal peptide (Ld) of the nonstructural protein
1 of tick-borne encephalitis virus (NS1 of TBEV). NS1 is
synthesized as a monomer and dimerizes after the posttrans-
lational modiﬁcation; it is also expressed on the cell surface
and is secreted as a hexamer [21–23]. Ld peptide is responsi-
ble for the presentation of NS1 on the cellular surface and
further secretion [24–26]. We characterized the properties
of Ld-RT1.14 chimera such as the half-life, route of degrada-
tion, eﬃcacy of secretion, capacity to induce oxidative stress,
and oxidative stress response and, ﬁnally, studied its perfor-
mance in DNA immunization in a mouse model. Retargeting
of RT to ER with subsequent secretion resulted in an increase
in the RT expression levels due to protein stabilization and
also, interestingly, in the nearly complete inhibition of the
residual polymerase activity retained in the inactivated RT.
Secretion led to a mild reduction of oxidative stress, but no
signiﬁcant enhancement of the cellular immune response
in the experimental DNA immunization. Immune response
to RT remained tinted towards the production of RT-speciﬁc
antibodies, typical to M2 polarization of macrophages
and Th2 polarization of T-cells in the settings of oxidative
stress [27–29].
2. Materials and Methods
2.1. Plasmids. Expression-optimized gene encoding reverse
transcriptase derived from the patient infected with
multidrug-resistant HIV-1 clade B isolate (RT1.14, [18]) with
mutations D185N, D186N, and E478Q abrogating polymer-
ase and RNase H activities was cloned into pVax1 vector
(Invitrogen, USA) generating pVaxRT1.14opt-in which was
described by us earlier [19]. Sequence encoding RT1.14opt-
in was used as a backbone to design a chimeric gene encod-
ing RT1.14 with the N-terminal insertion of the leader
sequence of NS1 protein of TBE. The latter was cloned from
plasmid pLdNS1 carrying the gene of NS1 protein ofWestern
European subtype of TBE [24]. The cloned fragment encoded
25 amino acids of a leader sequence ofNS1 and theN-terminal
methionine for an eﬀective initiation of translation. This
fragment including 78 nucleotide b.p. was ampliﬁed with
KAPA HiFi Hot Start DNA polymerase (Kapa Biosystems,
USA) and Ld-NheI-F (5′-ATA-CGC-AAG-CTA-GCA-
ATA-TGA-GAA-ACC-CTA-CAA-TG-3′) and Ld-BamHI-
R (5′-TCT-AAC-AGG-ATC-CCG-CCC-CCA-CTC-CAA-
GGG-3′) primers (Syntol, Russia), containing restriction
sites NheI and BamHI, respectively. Resulting PCR product
was cloned at the 5′-terminus of RT1.14 gene using NheI
and BamHI restriction sites. Fusion of NS1 Ld- and
RТ1.14opt-in-encoding fragments formed one open-reading
frame encoding optimized inactivated leader-fused RT1.14,
dubbed RT1.14oil, within the plasmid pVaxRT1.14oil. Nucle-
otide sequence of the cloned fragment was conﬁrmed by
sequencing. For immunization, plasmids were puriﬁed using
Plasmid Endofree kits (Qiagen, Germany) as described by
the manufacturer.
2.2. Expression of Homo- and Heterodimers of Reverse
Transcriptase in E. coli. For expression in E. coli genes of
active and inactivated RT, HIV-1 HXB2 and RT1.14 were
cloned into a two-cistron vector pET-2c. Proteins were
expressed inE. coli andpuriﬁedby ion exchange chromatogra-
phy as homodimers using the protocol described earlier [30].
Wild-type p66/p51 heterodimeric HIV-1 RT was expressed
in M-15 [pREP4] E.coli strain transformed with the plasmid
p6HRT [31] and puriﬁed as previously described [32].
2.3. RT Polymerase Activity Assay. The RT assays using acti-
vated DNA were performed as follows: the standard reaction
mixture (20μl) contained 0,75μg of activated DNA, 0,02–
0,05μg RT, 3μM dATP, 30μM of dCTP, dGTP, and dTTP,
1μCi [a-32P]dATP in a Tris-HCl buﬀer (50mM, pH 7,5)
containing also 10mM MgCl2, and 0,2M KCl. The reaction
mixtures were incubated for 12 minutes at 37°C and applied
onto Whatman 3MM ﬁlters with a 0,5M EDTA solution to
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stop reaction. After drying on air, the ﬁlters were washed
twice with 10% trichloracetic acid, then twice with 5% tri-
chloracetic acid, and once with ethanol and dried on air.
The radioactivity was measured by the Cherenkov method
[33]. Radioactivity was determined using a Tri-Carb 2810
TR scintillation counter (Perkin Elmer, USA).
2.4. RNase H Activity Assay. RNase H activity assay of HIV-1
RT was tested by using 6,7mmol of 18-ribo-Fl/18-deoxy
duplex (18-mer oligoribonucleotide (18-ribo-Fl: 5′-r(GAU-
CUGAGCCUGGGAGCU)-ﬂuorescein-3′) and 18-mer oligo-
deoxyribonucleotide (18-deoxy d5′-d(AGCTCCCAGGCTC
AGAUC)-3′)). RNA/DNA duplex was added to reaction
mixtures consisted of 15μL of 50mM Tris/HCl (pH 8,0),
containing 60mM KCl, 10mM MgCl2, and various concen-
trations of p66/p51 RT variant (5, 20, 100, and 400nM)
followed by a 15min incubation at 37°C. The reaction was
stopped by adding 80μl of 7mM EDTA, 0,375M sodium
acetate, 10mM Tris-HCl (pH 8,0), and 0,125mg/ml glyco-
gen. The mixture was extracted by phenol/chloroform, and
RNA/DNA fragments were precipitated with ethanol. The
reaction products were separated by electrophoresis in a
20% polyacrylamide/7M urea gel (PAGE). Gel images were
recorded using Typhoon FLA 9500TM Phosphorimager
(Molecular Dynamics, Israel) and then quantiﬁed using
Quantity One 4.6.6. (Bio-Rad, USA). The experiments were
conducted three times.
2.5. Eukaryotic Cell Cultivation and Transfection. HeLa and
HEK293T cells were cultivated at 37°C in 5% CO2 in DMEM
medium (PanEco, Russia) supplemented with 10% of fetal
bovine serum (FBS; HyClone, USA) and 100μg/ml of strep-
tomycin/penicillin mixture. Transfection was performed
with Lipofectamine LTX (Invitrogen, USA) in accordance
with manufacturer’s instructions. Cells were grown for 48
hours, cells were harvested, and cell culture ﬂuids were col-
lected and used for further analysis of RT expression, studies
of oxidative stress, and RT polymerase activity.
2.6. Immunostaining of RT Expressing Eukaryotic Cells. HeLa
cells were grown and transfected on the cover glass
(20× 20mm) in the 6-well cell culture plates (Corning,
Costar, USA). Two days posttransfection, cells were ﬁxed
with methanol-acetone (1 : 1). After ﬁxation, cells were incu-
bated in the staining buﬀer (PBS, 2% BSA, 0,2% Tween 20,
and 10% glycerol) containing monoclonal murine anti-RT
(1 : 10) or polyclonal rabbit anti-RT (1 : 100) and subse-
quently stained with FITC-conjugated anti-murine or anti-
rabbit antibodies (1 : 50) (Dako, Denmark) as described
previously [12]. Cell nuclei were stained with DAPI ﬂuoro-
chrome (Invitrogen, USA). For surface protein analysis, cells
were ﬁxed with 2% paraformaldehyde, then blocked with 5%
BSA in PBS, and incubated with anti-RT antibodies diluted
in the staining buﬀer without Tween 20. Slides were read
on the confocal microscope Leica TCS5 (Leica, Germany).
2.7. Quantiﬁcation of RT Expression in Eukaryotic Cells and
Cell Culture Fluids by Western Blotting. RT1.14-expressing
HeLa were lysed and analyzed by Western blotting using
polyclonal rabbit anti-RT [34] or monoclonal murine anti-
RT antibodies [35] as primary and anti-rabbit or anti-
mouse HRP-conjugated antibodies as secondary (Jackson,
USA) as was previously described [12]. Cell culture ﬂuids
were centrifuged at 5000×g and then concentrated approxi-
mately 10 times with Vivaspin 500 units (Sartorius Stedim,
Germany) with a 30,000 MWCO membrane. Concentrated
culture ﬂuid was mixed with Laemmli buﬀer and then sub-
jected to Western blotting same way as the cell lysates.
Immune complexes on the membrane were detected with
ECL (Amersham, USA) and X-ray ﬁlm (FujiFilm, Japan).
The data was processed in ImageJ software (http://rsb.info.
nih.gov/ij). After RT-speciﬁc staining, blots were washed
and restained ﬁrst with monoclonal anti-β-actin murine
antibodies (Sigma, USA) and then with anti-mouse HRP-
conjugated antibodies (Dako, Denmark). To assess the level
of RT expression per cell, the percent of cells expressing RT
was estimated from the eﬃcacy of transfection established
in a control cotransfection with GFP plasmid (peGFP-N1,
Novagen, Germany) used as a reporter. The number of cells
for each sample was counted with hemocytometer and cer-
tain number of cells was taken for Western blotting analysis.
The number of transfected cells was estimated from the per-
centage of transfection eﬃcacy. The amount of RT protein in
the lysed cells and culture ﬂuids was calculated based on a
standard curve built using the recombinant RT 1.14 protein
and dispensed in serial dilutions in the concentration range
from 1 to 20 ng per well; the latter samples were analyzed
together with the lysates as described earlier [12]. RT content
per cell was calculated by dividing these values by the number
of transfected cells.
2.8. Quantiﬁcation of RT Polymerase Activity in Cell Lysates
and Cell Culture Fluids. Two days posttransfection of HeLa
cells with pVaxRT1.14opt-in or pVaxRT1.14oil plasmids, cell
culture ﬂuids were collected and concentrated as described
above. Cells were lysed in TNEV buﬀer containing 50mM
Tris HCl (pH 7,5), 1% Triton X-100, 2mM EDTA, and
100mM NaCl supplemented with protease inhibitor cocktail
(Sigma, USA). RT activity in the cell lysates and cell culture
ﬂuids was assessed by Lenti RT activity kit (Cavidi, Sweden)
following instructions of the manufacturer. The amount of
protein determined by the polymerase activity assay was nor-
malized to the total amount of RT protein assessed by West-
ern blotting using the calibration curve built with the
recombinant RT1.14 protein in a concentration range from
1 to 20 ng per well. The data obtained represented the relative
polymerase activity of the samples.
2.9. Measurement of Reactive Oxygen Species. Measurement
of reactive oxygen species was performed as described earlier
[36]. In brief, 40 hours posttransfection, HEK293T cells were
incubated for 30min in cell culture medium containing
25μM 2′,7′ dichlorodihydroﬂuorescein diacetate (DCFH).
Fluorescence intensities were measured using Plate CHAME-
LEON V reader (Hidex Ltd., Finland) with the excitation at
485 nm and emission at 535 nm.
2.10. Reverse Transcription andQuantitative PCR (RT-qPCR).
RNAwas isolated from5× 105 transfectedHEK293Tcellswith
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PerfectPure RNA Cultured Cell kit (5 Prime, Germany, USA)
and then transcribed with Reverse Transcription System
(Promega, USA) with random hexamer primer according to
manufacturer’s protocol. RT-qPCR was performed using iQ5
Real-TimePCRDetection System (BioRad,USA) andprimers
andprobeswhichwere described earlier [36].A standard reac-
tion mixture (50μl) contained Taqman primer/probe combi-
nation, cDNA equivalent to 100ng of total RNA, and qPCR-
HS master mix. The thermal conditions for PCR reaction for
all genes were 55°C for 5min, 95°C for 10min followed by 40
cycles at 95°C for 10 sec, and 57°C for 1min (signal collection
temperature). Relative quantitative analysis was performed
by comparing threshold cycle number for target genes and a
reference β-actin mRNA, ampliﬁed in separate tubes.
2.11. Degradation of RT in Eukaryotic Cells. The measure-
ment of half-life of the protein was done using the cyclohex-
imide chase assay based on the method described earlier [37].
For this, HeLa cells 48 hours posttransfection were treated
with cycloheximide (Sigma-Aldrich, USA) at the ﬁnal con-
centration 100 μg/ml. After 0, 2, 4, and 6 hours of incubation,
the cells were harvested, lysed, and analyzed byWestern blot-
ting. The half-life time for the protein was calculated with a
standard formula: Т1/2 =−0,693 t/lnN/N0, where N0 is the ini-
tial amount of protein and N the amount of protein at time t.
To evaluate the role in RT degradation of the proteasome and
lysosome inhibitors, HeLa cells were transfected with pVaxR-
T1.14opt-in or pVaxRT1.14oil and 24 hours posttransfection
treated with the cellular protease inhibitors at the ﬁnal
concentrations indicated in the brackets: E64 (10μM),
leupeptin (10μg/ml), aprotinin (10 μg/ml), pepstatin A
(7,5μM), MG132 (5 μM), or epoxomicin (0,1 μM) (all from
Calbiochem, USA). After 18 hours of incubation with the
inhibitors, cells were lysed and the residual amount of RT
was estimated by Western blotting.
2.12. DNA Immunization of Mice. Eight-week-old BALB/c
mice (8 weeks, Charles River Laboratories, Sandhofer,
Germany) were housed under a light-dark (12 h/12 h) cycle
with ad libitum access to water and food. Animals were anes-
thetized by a mixture of 4% isoﬂurane with oxygen and
maintained in 2,3% isoﬂurane ﬂow administered through
facial masks during all intradermal injections and electropo-
ration. All experimental procedures were approved by the
local ethical committee. Groups consisting of 4–6 mice were
injected with 10μg of pVaxRT1.14opt-in or pVaxRT1.14oil,
or with empty pVax1 vector, mixed with equal amount of
pVaxLuc encoding ﬁreﬂy luciferase administered with 29G
insulin needles in 20μl of PBS. Each mouse got two intrader-
mal DNA injections, to the left and to the right of the base of
the tail. Immediately after, injection sites were subjected to
electroporation using DermaVax DNA vaccine delivery
system (Cellectis Glen Burnie, France) as described earlier
[38]. In day 21 postimmunization, mice were bled and
sacriﬁced and their spleens were collected.
2.13. Analysis of Cellular Immune Response
2.13.1. INF-γ and IL-2 Fluorospot. The spleens of immunized
mice were homogenized, and the splenocytes were isolated as
described in [8]. The cells were incubated in RPMI medium
supplemented with 2mM L-glutamine, 100μg/ml of strepto-
mycin/penicillin mixture (all from Sigma-Aldrich, USA), and
10% FBS (Gibco, Invitrogen, USA) (complete media), with
the following antigens taken in concentration 10μg/ml:
synthetic peptides corresponding to RT aa375-389 (ITTESI-
VIWGKTPKF), 465-476 (KVVPLTNTTNQK), 514-528
(ESELVNQIIEQLIKK), 528-543 (KEKVLAWVPAHKGIG),
leader sequence of NS1 (RNPTMSMSFLLAGGLVLAM
TLGVGA) (all peptides from GL Biochem Ltd., China) and
RT 1.14 protein. Concanavalin A (ConA, 5 μg/ml) was used
as a positive control and cell culture medium as a negative
control. After 20 hours of incubation, IFN-γ and IL-2 secre-
tion by splenocytes was assessed by dual IFN-γ/IL-2 Fluoro-
spot (Mabtech, Sweden) in accordance with the protocol
provided by the manufacturers. The number of cells secreting
cytokines was calculated with ﬂuorimeter AID ELISpot
(Autoimmun Diagnostika GmbH, Germany).
2.13.2. Detection of Secreted Granzyme B and Perforin by
Splenocytes. Isolated murine splenocytes were applied on
96-well V-plates in 200μl RPMI-10% FBS and stimulated
in duplicates with the recombinant RT1.14 protein and RT
peptides, same as used in Fluorospot test (10μg/ml). Cells
were incubated for 3 days at 37°C and 5% CO2. After that,
100μl of cell culture ﬂuid from each well was collected, dupli-
cates were pooled, redivided into two 100μl aliquots, and sub-
jected to analysis by sandwich ELISA for granzyme B (DuoSet
Development kit; R&D Systems Europe Ltd.) and perforin
(PRF1; Hölzel Diagnostika Handels GmbH, Germany). Kits
were used as recommended by the manufacturers.
2.14. Detection of Anti-RT Speciﬁc Antibodies by Indirect
ELISA. 96-well microtiter plates (Nunc Maxisorp, Denmark)
were coated with recombinant RT1.14 protein or NS1 Ld
peptide diluted in PBS at 0,3 μg/ml by overnight incubation
at 4°C. Solution was discarded, and plates were washed with
PBS containing 0,05% Tween 20. Individual mice sera diluted
in HIV-scan buﬀer (2% normal goat serum, 0,5% BSA, 0,05%
Tween 20, and 0,01% sodium merthiolate) in ﬁve (IgA syb-
type) or three (IgG subtypes) fold-steps starting from 10
(IgA) or 200 (IgGs) were applied on the plates and incubated
overnight at 4°C. The plates were washed as above, and
HRP-conjugated goat anti-mouse IgG or IgA (Sigma, USA)
diluted in HIV-scan buﬀer was applied and incubated for
1,5 hours at 37°C. After the incubation, plates were washed
as above and color reaction was developed with 3,3′,5,5′- tet-
ramethylbenzidine substrate solution (TMB; Medico-
Diagnostic Laboratory, Russia). Reaction was stopped by
addition of 50μl of 2,5M of sulfuric acid, and optical density
was recorded at a dual wavelength of 450 and 650 nm. The
cutoﬀ for speciﬁc RT antibody response was set as mean
OD values showed by sera of vector-immunized mice at this
timepoint +3SD.Forpositive sera showingODvalues exceed-
ing the cutoﬀ, endpoint dilution titers were established from
the titration curves.
2.15. In Vivo Monitoring of Reporter Expression. Biolumines-
cence emission from the area of DNA-immunogen/Luc gene
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injection was analyzed days 1, 3, 9, 15, and 22 postimmuniza-
tion. To estimate luciferase expression in vivo, mice were
intraperitoneally injected with the solution of D-luciferin
(Perkin Elmer, USA) in PBS in 15mg/ml at a dose of 100 μl
for 10 g of body weight and left for 5 minutes. In vivo imaging
of bioluminescence was performed with a highly sensitive
CCD camera, mounted in a light-tight chamber (Spectrum
CT, Perkin Elmer, USA). Anesthesia was induced by 4% iso-
ﬂurane and maintained by 2,3% isoﬂurane throughout the
imaging procedure. Camera exposure time was automatically
determined by the system and varied between 1 and 60 s
depending on the intensity of the bioluminescent signal.
Regions of interest were localized around the injections sites
and were quantiﬁed as the total luminescence ﬂux in pho-
tons/s. CT/BLI data were processed using the Living Image®
software version 4.1 (Perkin Elmer, USA) to generate values
of total photon ﬂux and mean photon ﬂux (photons/sq cm)
from the injected area.
2.16. Statistics. Statistical evaluations were done using STA-
TISTICA AXA 10.0 (StatSoft Inc., OK, USA). Nonparametric
statistics was chosen as appropriate for sample sizes <100
entries. Continuous but not normally distributed variables,
such as the average radiance in photons/s/cm2/Sr, antibody
titers, or the number of cytokine-producing SFCs, cytokine
levels in pg/ml, were compared in groups by the nonpara-
metric Kruskal-Wallis and pairwise by Mann–Whitney U
test. Correlations were run using the Spearman rank order
test. p values <0.05 were considered signiﬁcant.
3. Results
3.1. Design and Expression of the Inactivated Multidrug
Resistant RT Fused to the Leader Peptide of TBEV NS1
(RT1.14oil). The secretable RT chimera was designed based
on the plasmid pVaxRT1.14opt-in [19] which encodes an
inactivated multidrug-resistant RT variant (RT1.14opt-in).
Original RT1.14 amino acid sequence originated from HIV-
1 clade B isolate from patient with multiple drug resistance
[18] modiﬁed by mutations introducing two D/N substitu-
tions in the polymerase YMDD motif, and one E/Q substitu-
tion in the RNase H DEDD motif, shown earlier to inhibit
respective enzymatic activities [39–42]. Inactivation of the
polymerase and RNase H moieties of RT was conﬁrmed in
in vitro assays done on the “classical” RT derived from
HIV-1 HXB2 strain and its analogue inactivated by D185N,
D186N, and E478Q mutations, represented, for adequate
characteristics of the enzymatic activity, by p51/p66 hetero-
dimers (Supplementary Figure S1 available online at https://
doi.org/10.1155/2017/7407136). Introduction of D185N
and D186N mutations completely abrogated the polymerase
activity of the enzyme (Figure S1A). We have also assessed
the RNase H activity of the active and inactivated RTs (Figure
S1B, C). The wild-type RT demonstrated signiﬁcant activity
in a broad range of enzyme concentrations tested (Figure
S1B, C). The eﬃcacy of hydrolysis of the 18-mer RNA/
DNA hybrid duplex strongly depended on the enzyme con-
centration (Figure S1B, C). On the contrary, RT inactivated
with mutation E478Q in the RNase H moiety was practically
inactive even at high enzyme concentrations; the eﬃciency
of hydrolysis was reduced by over 90% compared to the
wild-type enzyme. These results conﬁrmed the adequacy of
inactivation strategy used to generate the inactivated drug-
resistant HIV RT.
Todesign the secreted formof inactivatedRT1.14,we used
a specialized signal of theheterologous viral protein, namely of
the nonstructural protein 1 of tick-borne encephalitis virus
(TBEV NS1) [24] (Figure 1). The leader signal of TBEV NS1
(Ld) consisting of the last 25 amino acid residues of TBEV
envelope protein (glycoprotein) E is responsible for the
transport to ER and secretion of the downstream NS1 pro-
tein [25, 26]. DNA sequence encoding LdNS1-RT1.14opt-
in chimera was generated by PCR and cloned into pVax1
vector yielding a plasmid dubbed pVaxRT1.14oil (Figure 1).
We have then compared the expression proﬁles of the
parental inactivated RT1.14 and of Ld-RT1.14 chimera. For
this, we transfected HeLa cells with pVaxRT1.14opt-in and
pVaxRT1.14oil plasmids; 48 hours posttransfection, cell
lysates and cell culture ﬂuids were collected and analyzed by
Western blotting. Lysates of cells fromboth transfections con-
tainedproteinswithmolecularmassof 66 kDa coincidingwith
the expectedmolecularmass of RT1.14 [43] (Figure 2(a)). The
amount of the 66 kDa product detected in the lysates of cells
transfected with pVaxRT1.14oil was approximately 1,4 times
higher than in the lysates of cells transfected with the parental
RT1.14opt-in gene (Figure 2(a)). Both lysates contained also a
protein with the molecular mass of 51 kDa corresponding the
polymerase subunit of HIV-1 RT [44]. Besides, lysates of cells
transfectedwith pVaxRT 1.14oil contained products of higher
molecular mass (over 170 kDa) that were speciﬁcally stained
with anti-RT antibodies; suggestively, the aggregates formed
as a result of RT overexpression. RT1.14opt-in was found in
the cellular fraction and, interestingly, in equal amounts, in
the cell culture ﬂuid from the expressing cells (Table 1). Ld-
RT1.14 chimera encoded bypVaxRT1.14oilwas preferentially
(>70%) found in the cell culture ﬂuid (Table 1).
3.2. Enzymatic Activity of RT in the Expressing Cells and in
the Culture Fluids. Next, we analyzed the lysates of cells
transfected with RT1.14opt-in and RT1.14oil genes for the
polymerase activity of RT by an ELISA-based test (Cavidi,
Sweden). We also collected, concentrated, and subjected
to the HIV RT activity test samples of the cell culture
ﬂuids. RT protein content in these probes was estimated
by Western blotting.
A residual RT polymerase activity was detected in all
probes, but not in the probes from nontransfected HeLa cells.
We evaluated the speciﬁc RT activity per 105 of HeLa cells
transfected with RT1.14opt-in and with RT1.14oil coding
plasmids. Lysates of 105 cells expressing RT1.14opt-in had
RT activity corresponding to 9,8 pg of the active protein, that
is, retained 0,00012% activity (9,8 pg of the active form in the
total 8,3μg of the enzyme by Western blotting; Table 1).
Lysates of 105 cells expressing RT1.14oil retained 0,00005%
of the activity (5,7 pg of the active form in the total 11,3μg
of the enzyme; Table 1). At the same time, cell culture ﬂuids
of RT1.14opt-in expressing cells retained 0,00053% of the
activity (74,4 pg out of 14μg), which is four times more than
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the speciﬁc activity in the cells (Table 1). The latter pointed
that RT1.14opt-in is secreted in the active form even without
the signal peptide. On contrary, cell culture ﬂuids of
RT1.14oil-expressing cells contained only 0,000014% of the
active enzyme (4,9 pg per 34,6μg), that is, 3,5 times less than
the lysates of RT1.14oil-expressing cells (Table 1). Thus,
RT1.14oil was eﬀectively secreted, but almost exclusively in
the inactive form.
3.3. RT Localization in the Expressing Eukaryotic Cells. Intra-
cellular localization of RT variants was investigated by the
immunoﬂuorescence microscopy. HeLa cells were trans-
fected with pVaxRT1.14opt-in and pVaxRT1.14oil plasmids
and subsequently stained with anti-RT and then FITC-
conjugated secondary antibodies. RT1.14opt-in was distrib-
uted in cell cytoplasm homogeneously (Figure 3(a)),
whereas the distribution of RT1.14oil was more granular
(Figure 3(b)). Besides, cultures of the cells transfected with
pVaxRT1.14oil plasmid were characterized by the presence
of granules speciﬁcally stained with anti-RT antibodies that
were localized inside and outside the cells and on the cell
surface (Figure 3(b), indicated by arrows). To conﬁrm the
cell surface localization of the protein, transfected cells were
ﬁxed with 2% paraformaldehyde with subsequent staining in
the absence of detergent. Surface of the cells transfected with
the initial plasmid pVaxRT1.14opt-in was not speciﬁcally
stained (Figure 3(c)), whereas the surface of pVaxR-
T1.14oil-transfected cells was speciﬁcally stained with anti-
RT antibodies (Figure 3(d)). To localize RT in relation to
ER, HeLa cells were treated with TRITC-conjugated anti-
bodies to an ER marker calreticulin, and FITC and TRITC
signals were overlaid (Figures 3(e) and 3(f)). In the case of
RT1.14oil, RT-speciﬁc signal was partially colocalized with
ER marker and partially with the secretory vesicles, whereas
RT1.14opt-in had a more prominent colocalization with ER.
3.4. RT Protein Degradation. Next, we estimated the speed of
degradation of RT1.14oil in HeLa cells and investigated the
contribution of cellular proteases into its proteolysis. To esti-
mate the half-life of the protein, cells transiently expressing
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Figure 1: Schematic representation of chimeric drug-resistant HIV-1 reverse transcriptase carrying the N-terminal insertion of the N-
terminal signal peptide of NS1 protein of TBEV (RT1.14oil). Rectangular boxes stand for polypeptide chains of NS1 with leader signal
peptide (white) and RT1.14opt-in sequence (gray) with amino acid substitutions in polymerase (D185N, D186N) and RNase H signature
motives (E478Q) leading to inactivation of respective enzymatic activities in the resultant RT1.14oil polyprotein. Amino acid positions in
the polypeptide chain are designated with numbers.
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Figure 2: Expression of HIV-1 RT1.14 fused to the N-terminal signal peptide of NS1 protein of TBEV in HeLa cells resolved by SDS-PAGE.
(a) Western blotting of the lysates of HeLa cells transfected with pVax1 (1), pVaxRT1.14opt-in (2), and pVaxRT1.14oil (3) plasmids; upper
panel, membranes stained with anti-RT; lower panel, with anti-β-actin antibodies for signal normalization. (b)Western blotting of the culture
ﬂuids of cells transfected with pVax1 (1), pVaxRT1.14opt-in (2), and pVaxRT1.14oil (3). Blots were stained with the speciﬁc polyclonal anti-
RT antibodies as described in the experimental section “Materials andMethods.” To control equal loading of the samples of cell lysates on the
gel, membranes were for the second time stained with anti-β-actin antibodies. Positions of the molecular mass markers are given to the left.
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RT1.14oil, or RT1.14opt-in, were after two days treated with
cycloheximide and lysed 0, 2, 4, and 6 hours after the on-start
of the treatment. The amount of RT1.14opt-in and RT1.14oil
in the probes was detected by Western blotting (Figure 4(a)).
The half-life of RT1.14opt-in was estimated as 2 and of
RT1.14oil as more than 8 hours (approximately 15 hours)
which characterizes it as a long-living protein (Figure 4(b)).
For a detailed study of RT proteolysis, on the next day
after the transfection, cells were treated with the inhibitors
of proteasomal and lysosomal proteolysis. The role of
proteasome in degradation was assessed using reversible
(MG132) and irreversible (epoxomicin) proteasomal inhib-
itors. Lysosomal proteolysis was blocked with the inhibitors
of cysteine (E64, leupeptin), serine (aprotinin, leupeptin),
and acid proteases (pepstatin A). Cells were incubated with
the inhibitors for 18 hours and lysed, and RT content was
estimated by Western blotting in comparison with the con-
tent in the untreated samples (Figure 5(a)). Treatment with
MG132 increased RT1.14opt-in content 2,5, and with
epoxomicin, 3 times compared to untreated samples;
lysosomal inhibitors had no eﬀect. None of the inhibitors
had any eﬀect on the intracellular level of RT1.14oil
(Figures 5(b) and 5(c)).
3.5. Induction of Oxidative Stress and Oxidative Stress
Response in RT1.14-Expressing Cells. Next, we have evaluated
the level of oxidative stress induced by RT1.14opt-in and
RT1.14oil in HEK293T cells transiently transfected with their
genes. Oxidative stress was measured by the formation of
reactive oxygen species (ROS) visualized in the presence
of ﬂuorogenic 2, 7′-dichloroﬂuorescein. The presence of
both RT variants in cells led to the formation of ROS
(Figure 6(a)). Interestingly, secretion resulted in a weak
but signiﬁcant decrease in the levels of ROS production
(15%; p = 0 013; F test; Figure 6(a)). Next, we have studied
the induction of oxidative stress response, namely, the
induction of expression of phase II detoxifying enzymes,
heme oxygenase 1 (HO1), and NAD(P)H-oxygenase 1
(Nqo1). Level of transcription of their genes was evaluated
by RT-PCR. Expression of RT variants led to an increase
in the levels of expression of both detoxifying enzymes
(Figure 6(b)). Cells expressing RT1.14oil demonstrated an
increase in the expression of Nqo1 (p < 0 05; F test;
Figure 6(b)) and a tendency to the increased induction of
HO1 (p = 0 07; F test; Figure 6(b)).
3.6. RT1.14 Performance in DNA-Immunized Mice. BALB/c
mice were injected with pVaxRT1.14opt-in, pVaxRT1.14oil,
or pVax1 plasmids intradermally with subsequent electropo-
ration. On day 22, mice were sacriﬁced; blood and spleens
were collected. Splenocytes were isolated and tested for the
ability to proliferate after in vitro stimulation with RT-
derived antigens. Immune response was evaluated as the pro-
duction of IFN-γ and IL-2 by Fluorospot and perforin and
granzyme B by sandwich ELISA. RT1.14opt-in- and
RT1.14oil-immunized mice demonstrated similar levels of
cellular response against the recombinant RT1.14 protein
(Figure 7(a)). Immunization with DNA encoding RT1.
14opt-in and RT1.14oil induced a weak IFN-γ and IL-2
response against a CD4+ T cell epitope of RT localized at aa
528-543 [45], which tended to be stronger in mice DNA
immunized with RT1.14oil (Figure 7(b), p < 0 1). Peptides
representing other known epitopes of RT induced no speciﬁc
IFN-γ or IL-2 production (data not shown). Interestingly,
splenocytes of mice DNA immunized with RT1.14oil
responded to stimulation with these peptides by a strong pro-
duction of perforin (Figure 7(c)). Levels of perforin secretion
signiﬁcantly correlated to the levels of RT-speciﬁc pro-
duction IFN-γ and IL-2 (Figure 7(e); R values >0,8;
p < 0 0005). On contrary, mice DNA immunized with
RT1.14opt-in responded to stimulation with RT-derived
peptides by a high-level production of granzyme B which
was not correlated to either IFN-γ or IL-2 levels
(Figure 7(d), data not shown). IFN-γ/IL-2 responses
have also been tested in splenocytes stimulated with a
peptide encoding a leader sequence of NS1 (NS1 leader
peptide). No speciﬁc cytokine secretion was detected
(data not shown).
Murine sera collected at the endpoint of the experiment
were analyzed for anti-RT antibodies by indirect ELISA. No
signiﬁcant diﬀerence was detected in antibody titers reached
in both groups of RT-immunized mice. Titers of IgG and
IgG1 exceeded 50,000 in both groups, IgG2a reached 15,000
in RT1.14opt-in and 6000 in RT1.14oil-immunized mice
and IgA 5000 in RT1.14opt-in and 6000 in RT1.14oil-immu-
nized mice, respectively (Figure 8). Ratio of IgG2a/IgG1 was
equal to 0,15 in both groups of mice indicating a Th2 type of
immune response [46]. TBEV NS1 Ld peptide induced no
speciﬁc antibodies (data not shown).
3.7. Eﬀector Immune Response to RT and Its In Vivo
Evaluation. We have earlier shown that diminishment of
Table 1: Expression, secretion, and residual enzymatic activity of inactivated forms of HIV reverse transcriptase RT1.14opt-in and RT1.14oil
in transiently transfected HeLa cells. RT content was determined by Western blotting using protein calibration curves with signal
quantiﬁcation by ImageJ (dubbed WB, in μg/105 cells) and by quantiﬁcation of enzymatic activity against standard RT preparation using
Lenti RT activity test (Cavidi, Sweden) (dubbed EA, in pg/105 cells). RT content in cell lysates is dubbed “in cells” and in cell culture ﬂuids
“secreted.” Speciﬁc activity was measured as a ratio of protein content evaluated using the enzymatic activity assay to RT content
determined by Western blotting.
RT variant
RT content by WB, μg/105 cells RT content by EA, pg/105 cells
Speciﬁc RT activity
(EA/WB), μU
In cells Secreted Total In cells Secreted Total In cells Secreted
RT1.14opt-in 8,30 14,00 22,30 9,80 74,40 85,00 1,18 5,30
RT1.14oil 11,30 34,60 46,00 5,70 4,90 11,00 0,51 0,14
7Journal of Immunology Research
RT1.14opt-in
(a)
RT1.14oil
(b)
RT1.14opt-in
(c)
RT1.14oil
(d)
RT1.14opt-in
(e)
RT1.14oil
(f)
Figure 3: Cellular localization of RT without signal of secretion (RT1.14opt-in) and with a signal peptide (RT1.14oil) in HeLa cells. HeLa cells
were transfected with the plasmids pVaxRT1.14opt-in (a, c, e) and pVaxRT1.14oil (b, d, f), grown on slides for 48 hours, ﬁxed with
methanol : acetone (1 : 1 v/v) (a, b, e, f) or 2% paraformaldehyde (c, d), and stained ﬁrst with polyclonal anti-RT and with secondary
FITC-conjugated anti-rabbit antibodies. For localization of RT in relation to ER, HeLa cells were treated with TRITC-conjugated
antibodies to an ER marker calreticulin (e, f), and the overlay of FITC and TRITC signals is shown.
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bioluminescence induced by the expression of reporter gene
coinjected with DNA immunogen correlates with the induc-
tion of polyfunctional cellular responses against the immu-
nogen [8, 47] speciﬁcally with IFN-γ/Il-2 responses of CD4
T cells [8]. To monitor this eﬀect, mice were coinjected with
RT gene variants and a reporter gene encoding ﬁreﬂy lucifer-
ase (Luc) and assessed for the levels of bioluminescence on
days 1, 3, 6, 9, 15, and 22 postimmunization. We have
observed a signiﬁcant diminishment of in vivo luminescence
after day 9 in all immunized mice, independently of the
enzyme form (Figure 9).
4. Discussion
Multiple eﬀorts made by us, and by others, to enhance the
immunogenicity of HIV-1 RT had limited success [12–14,
16–18]. Recently, we discovered that both the wild-type
and drug-resistant RT variants induce oxidative stress in
the expressing cells [19]. Oxidative stress has a dual impact
on the development of immune response, and low to moder-
ate levels of stress may be stimulating, whereas excessive
stress aﬀects both the innate and adaptive immune response
[48–51]. High levels of oxidative stress detected in the RT-
expressing cells during DNA immunization may suppress
the development of speciﬁc immune response. We hypothe-
sized that this eﬀect can be neutralized or minimized by an
early export of RT from the expressing cells. To test this,
we supplemented RT with the leader signal peptide of NS1
protein of TBEV, responsible for cotranslational transloca-
tion of the carrier proteins into ER with subsequent secre-
tion [25, 26]. As the backbone for this chimera, we chose
the most immunogenic RT variant of the ones we have
tested so far, RT of HIV-1 clade B strain with multiple muta-
tions of drug resistance (RT1.14) [18] encoded by the
expression optimized gene. RT1.14 was devoid of the enzy-
matic activities by two D/N mutations in YMDD, and one
E/Q mutation in DEDD motives was shown to inhibit the
polymerase and RNase H activities, respectively [39–42].
We have proven that these mutations successfully abrogate
both activities of the model RT of HIV-1 HXB2 strain.
A chimera of the inactivated multidrug-resistant RT with
the leader peptide Ld of NS1 dubbed “Optimized Inacti-
vated with Leader sequence” RT1.14, or RT1.14oil, was
thus created.
Fusion of the leader peptide sequence changed localiza-
tion of the chimera. The distribution of RT1.14oil was more
granular in comparison to RT1.14opt-in. Also, in the case
of RT1.14oil, RT-speciﬁc signal was partially colocalized with
the ER marker and in part with the secretory vesicles, unlike
the parental RT1.14opt-in which had a more prominent ER
colocalization. RT1.14oil was detected in the cells and as
granules on the cell surface and in the intercellular space.
As expected, RT1.14oil was detected also in the cell culture
ﬂuids with three times more protein there than in the cells.
Altogether, this demonstrated the success of our strategy of
RT export. Leader peptide of TBEV NS1 can function as an
eﬃcient signal for targeting the heterologous proteins into
the secretory pathway. Detection of RT1.14oil both in the
cells (cell lysates) and in the cell culture ﬂuids was an
expected ﬁnding. We have also made an unexpected ﬁnding
of RT1.14opt-in not only inside the cells (in cell lysates) but
also in the cell culture ﬂuids. One of the explanations could
be the leakage from apoptotic cells dying due to oxidative
stress. However, we have not observed an abnormal/exces-
sive cell death of the RT-expressing cells neither in this nor
in the earlier studies [19]. The actual RT export/secretion
mechanism requires further elucidation.
Relocalization of RT1.14oil drastically changed its pro-
cessing. Firstly, its half-life increased from 2 to >8 hours.
While RT1.14opt-in was mainly degraded by proteasome,
RT1.14oil was insensitive to most of the cellular proteases
tested. Thus, retargeting of RT1.14oil into the secretory
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Figure 4: The kinetics of degradation of RT1.14opt-in and RT1.14oil in HeLa cells after blocking of translation with cycloheximide. (a)
Western blotting of HeLa cells transfected with pVaxRT1.14opt-in and pVaxRT1.14oil plasmids 0, 2, 4, and 6 hours after cycloheximide
treatment. The blots were stained with polyclonal anti-RT antibodies. To control equal loading of the samples on the gel, membranes were
restained with anti-β-actin antibodies. (b) Diagram of protein degradation speed. 100% is according to initial amount of the protein. The
graph is plotted in accordance with the results of 3 independent experiments, ±SD. ∗p < 0 05 (Mann–Whitney test).
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pathway led to its “escape” from both proteasomal and
lysosomal processing which resulted in accumulation of the
protein inside and outside of the cells.
By measuring the polymerase activity in the lysates and
cell culture ﬂuids of the expressing cells, we found that intro-
duction of the mutations in YMDD motif expected [42, 52]
and conﬁrmed here to completely abrogate the polymerase
activity of the wild-type HIV-1 RT could not completely
inactivate the multidrug-resistant enzyme. Both RT1.14opt-
in and RT1.14oil preparations had a residual activity on the
level of 0,0005% to 0,00005% of the activity of the equivalent
amount of RT of HXB2 strain. Secretion of RT increased
the biosafety, as we have observed that RT1.14oil was
signiﬁcantly less active than the parental RT1.14 both in
the cells and when secreted in the cell culture medium.
Onepossible explanation is in theRT-inducedoxidative stress.
Earlier, a phenomenon was described of the superoxide
radical-mediated inactivation of an enzyme (myeloperoxi-
dase) secreted by neutrophils [53]. Secreted RT1.14oil can
undergo a likewise inactivation. Inactivation can also be due
to the protein agglomeration following the accumulation of
high amounts of undegradable RT1.14oil protein. We
observed granular staining in the cytoplasm of RT1.14oil-
expressing cells, and proteins of high molecular mass were
speciﬁcally stained with anti-RT antibodies in Western
blotting of cell lysates, the latter indicating formation of
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Figure 5: RT accumulation in HeLa cells treated with inhibitors of proteasomal and lysosomal proteolysis. Western blotting of HeLa cells
transfected with pVaxRT1.14opt-in and pVaxRT1.14oil after 18-hour incubation with MG132 (5 μМ), epoxomicin (0,1 μМ), E64 (10 μМ),
leupeptin (10 μg/ml), aprotinin (10 μg/ml), and pepstatin А (7,5 μМ) or without inhibitors. The blots were stained with monoclonal anti-
RT antibodies. To control equal loading of the samples on the gel, the membranes were stripped and restained with anti-β-actin
antibodies (a). Relative content of RТ1.14opt-in and RТ1.14oil in the samples treated with proteasomal inhibitors (b). Relative content of
RТ1.14opt-in and RТ1.14oil in the samples treated with lysosomal inhibitors; no diﬀerence in response to lysosomal inhibitors between
RT1.14opt-in- and RT1.14oil-expressing cells was detected (all p values > 0,05) (c). In (b) and (c), protein content in the untreated
samples is taken for 1. Graphs in (b) and (c) represent the results of three independent experiments, +SD. ∗p < 0 05 (Mann–Whitney test).
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cross-linked protein agglomerates, similar to the observations
made for the near-infrared reporter proteins [54]. The latter
often results in the loss of enzymatic activity (protein func-
tion(s)) [55, 56]. Signal peptide-targeted secretion helped to
diminish the residual polymerase activity andmadeRT1.14oil
more attractive as the potential DNA vaccine component.
Artiﬁcial secretion resulted in a decrease of the capacity
of RT to induce oxidative stress with 15% decrease in the pro-
duction of ROS compared to the parental enzyme. This can
be explained by the induction of the ARE-dependent mecha-
nisms of oxidative stress response involving the enhanced
expression of phase II detoxifying enzymes, speciﬁcally
NAD(P)H-oxygenase 1. We have further inquired whether
a decrease in the level of oxidative stress induced by
RT1.14oil would improve its immunogenicity when deliv-
ered as DNA. We detected no signiﬁcant enhancement of
RT-speciﬁc immune response to RT1.14oil compared to
RT1.14opt-in. Both genes induced a similar loss in the
expression of luciferase reporter from the sites of immuniza-
tion indicating that an immune response induced by RT-
14opt-in and by RT1.14oil genes had a similar capacity for
in vivo clearance of RT-expressing cells. The only diﬀerence
was observed in the proﬁle of the secreted eﬀector molecules.
Mice DNA immunized with RT1.14oil responded by the
secretion of perforin, in which the latter correlated to the
levels of RT-speciﬁc dual secretion of IFN-γ/IL-2. In contrast,
mice DNA immunized with RT1.14opt-in responded by the
RT-speciﬁc secretion of granzyme B not correlated to the
production of either IFN-γ or IL-2. Thus, the enhancement
of secretion due to signal peptide tag led to no major changes
in the proﬁle of anti-RT cellular immune response with the
exception of a shift from the secretion of granzyme B in
response to RT1.14opt-in, in favor of perforin in the response
to RT1.14oil.
The addition of secretion signal is expected to pro-
mote antibody formation. Targeting for secretion of the
membrane-bound glycoprotein of viral haematopoietic septi-
caemia virus resulted in the enhancement of IgM response in
the rainbow trout [57]. DNA immunizationwith the cytoplas-
mic protein cathepsin B fused to the signal peptide of TPA
induced a twofold increase in the level of speciﬁc IgG [58].
However, here, secretion of RT1.14 caused no enhancement
of either IgG or IgA responses. Similar observations were
made earlier for the rabies glycoprotein that was originally
exposed on the cell surface and elicited strong antibody
response even prior to artiﬁcial secretion; addition of a secre-
tion signal gave no boost to the speciﬁc antibody response
[59]. Apparently, even comparatively low amounts of extra-
cellular immunogen (as in case of RT1.14opt-in) are capable
of eliciting high antibody production. Further increase in the
amounts of extracellular protein due to artiﬁcial secretion do
not promote further enhancement of humoral responses. Of
note, signal sequence of TBEVNS1 appeared to be nonimmu-
nogenic on either cellular or antibody levels, the latter favor-
ing its inclusion into the heterologous protein immunogens
as a noninterfering transport moiety.
Both the parental and the signal peptide-tagged RTs were
secreted. Enhancement of secretion due to signal peptide tag
induced only moderate decrease in the oxidative stress.
Hereby, we could extend our statement on the capacity of
RTs to induce oxidative stress: it is induced by a wide panel
of RT variants, wild-type and drug-resistant, expressed from
viral and from the expression-optimized genes [19], prefera-
bly secreted as well as preferably intracellular, both
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Figure 6: Induction of oxidative stress and oxidative stress response in cells expressing multidrug-resistant inactivated reverse transcriptase
RT1.14opt-in and its derivative RT1.14oil carrying a signal peptide. Induction of the oxidative stress was detected as the production of ROS
(a) and increase in the levels of mRNA of the phase II detoxiﬁcation enzymes Nqo1 and HO1 (b). Levels of ROS were normalized to those in
HEK293T cells transfected with the empty vector pVax1. Levels of mRNA for Nqo1 and HO-1 were normalized to levels of mRNA for actin
and then represented as fold diﬀerence to the eﬀect of empty vector pVax1. Data represent the results of two independent experiments, each
done in triplicate, +SD. Results are compared using F test (Statistica AXA 10), ∗p < 0 05.
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Correlation of IFN-훾, IL-2, and perforin production in response to splenocyte stimulation
with peptide RTaa528-543
IFN-훾 RT 528-543, CD4: IL-2 RT 528-543, CD4: R = 0,8092; p = 0,0001; R2=0,6547
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Figure 7: Cellular immune response of mice immunized with pVaxRT1.14opt-in and pVaxRT1.14oil. IFN-γ, IL-2, and dual (IFN-γ/IL-2)
secretion by splenocytes in response to stimulation with RT1.14 protein (a) or RT1.14-derived peptide aa528-543 (b) measured by
Fluorospot. Responses represent the average number of signal-forming units (sfu) per mln cells in two independent experiment runs, each
done in duplicate, +SD, n = 4, ∗∗p < 0 1 (Mann–Whitney test). Secretion of perforin (c) and granzyme B (d) by splenocytes of mice
immunized with pVaxRT1.14opt-in and pVaxRT1.14oil in response to stimulation with RT1.14 protein and RT1.14-derived peptides.
Splenocytes were stimulated with the recombinant RT 1.14 protein and RT peptides for 3 days. After that, cell culture ﬂuids were collected
and subjected to the analysis for granzyme B and perforin by sandwich ELISA. Data represent an average value of two repeated
measurements for each mouse, in pg/ml. Correlation of the parameters of cellular immune response (e).
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enzymatically active and inactive. Altogether, this indicates
that the propensity to induce oxidative stress and to modu-
late the immune response towards the antibody type is a
property of the protein not linked to its enzymatic activities
which can be modiﬁed and even abrogated.
We tentatively allocated this property to the RNase H
domain of HIV-1 RT. RNases are necessary for the mainte-
nance of cellular homeostasis, they participate in the degra-
dation of ribosomes/cleavage of tRNA; RNases are involved
in the recycling of phosphate during processes involving cell
death and, hence, in the control of apoptosis [60]. Cleavage of
tRNA by RNases is a conserved aspect of the response to oxi-
dative stress [61, 62]. A secreted ribonuclease angiogenin
selectively cleaves tRNA in eukaryotic cells; treatment of cells
with this recombinant RNase or cell transfection with prod-
ucts of angiogenin activity (tRNA fragments) inhibits protein
synthesis and induces apoptosis [62]. Overexpression of
another RNase, RNase T2 family Rny1p, also caused apopto-
sis in yeast cells, whereas the deletion of its gene inhibited the
apoptosis, speciﬁcally apoptosis in response to stress [63]. A
proapoptotic activity of HIV-1 RNAse H was recently
described [62]. Interestingly, Rny1p induced apoptosis inde-
pendently of the catalytic activity through (yet unknown)
interactions with the downstream components of the cata-
bolic cell cascades [63, 64]. These observations indicate that
oxidative stress induced by HIV RT expression may be linked
to the properties of the RNase H moiety of the enzyme, not
necessarily its activity. As Rny1p, inactive HIV-1 RNase H
may retain the capacity to interact with the cellular proteins
inducing oxidative stress and apoptotic cell death. By artiﬁ-
cial secretion of HIV RT, we made it more stable and failed
to reduce its content and, hence, the content of RNase H
inside the cells, which in its turn did not allow us to signiﬁ-
cantly improve RT immunogenicity. Indirect conﬁrmation
of this concept lies in the experiments by Hallengard et al.
who succeeded in raising strong immune response against
RT after truncation of a part of RNase H domain [17]. Fur-
thermore, we believe that the secretion that we found to be
characteristic to this enzyme may play a role in the develop-
ment of oxidative stress and oxidative stress response. Two
other HIV proteins known to induce oxidative stress which
contributes to HIV pathogenicity, namely, Tat and Vpr, are
also secreted [65, 66]. Entry into the intercellular space turns
Tat, Vpr, and possibly also RT into the signal molecules capa-
ble of aﬀecting neighboring, also uninfected, cells. The actual
mechanism(s) of the secretion of untagged RT and the input
of this process into the induction of oxidative stress and
modulation of immune response deserve a separate study.
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Figure 8: RT-speciﬁc IgGs and IgA induced in sera of mice
immunized with pVaxRT1.14opt-in and pVaxRT1.14oil plasmids.
Endpoint titers of RT-speciﬁc total IgG, IgG subtypes (IgG1,
IgG2a), and IgA antibodies detected in the sera of BALB/c mice
immunized with the genes encoding RT1.14opt-in and RT1.14oil
plasmids. Data represent a mean + SD for the endpoint titer of
antibodies against recombinant RT1.14 protein for four mice per
group in two independent immunization runs. Cutoﬀs were set
against the control mice immunized with empty vector pVax1 (see
“Materials and Methods”). Groups demonstrate no signiﬁcant
diﬀerence in either IgG, or IgG1, or IgG2a, or IgA levels (p > 0 05).
1 3 6 9 15 22
104
105
106
107
108
109
pVaxRT1.14opt-in
pVaxRT1.14oil
pVax1
Days post gene coinjection
Bi
ol
um
in
es
ce
nc
e (
p/
se
c/
cm
2 /
sr
) ⁎
⁎
Figure 9: Kinetics of in vivo bioluminescence from the sites of
coadministration of RT genes and luciferase reporter genes. In
vivo monitoring of luciferase activity on days 1, 3, 6, 9, 15, 22 after
the administration of plasmids encoding RT1.14opt-in and
RT1.14oil, or empty vector pVax1, each mixed with pVaxLuc
encoding ﬁreﬂy luciferase (1 : 1 w/w). One curve represents
bioluminescent emission from eight mice with two immunization
sites in each, assessed in two independent immunization runs.
∗p < 0 05 (Mann–Whitney test).
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